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Abstract
Objective. Chronic musculoskeletal pain (CMSP) disorders are among the most prevalent and disabling conditions
worldwide. It would be advantageous to have common outcome measures when comparing results across different
CMSP research studies. Methods. The Veterans Health Administration appointed a work group to recommend core
outcome measures for assessing pain intensity and interference as well as important secondary domains in clinical
research. The work group used three streams of data to inform their recommendations: 1) literature synthesis aug-
mented by three recently completed trials; 2) review and comparison of measures recommended by other expert
groups; 3) two Delphi surveys of work group members. Results. The single-item numerical rating scale and seven-
item Brief Pain Inventory interference scale emerged as the recommended measures for assessing pain intensity
and interference, respectively. The secondary domains ranked most important included physical functioning and de-
pression, followed by sleep, anxiety, and patient-reported global impression of change (PGIC). For these domains,
the work group recommended the Patient-Reported Outcome Information System four-item physical function and
sleep scales, the Patient Health Questionnaire two-item depression scale, the Generalized Anxiety Disorder two-item
anxiety scale, and the single-item PGIC. Finally, a single-item National Health Interview Survey item was favored for
defining chronic pain. Conclusions. Two scales comprising eight items are recommended as core outcome measures
for pain intensity and interference in all studies of chronic musculoskeletal pain, and brief scales comprising 13 addi-
tional items can be added when possible to assess important secondary domains.
Key Words: Pain; Low Back Pain; Psychometrics; Measures; Minimal Data Set
Musculoskeletal pain conditions account for 70–80% of
all chronic pain [1–3]. Low back pain (LBP), neck pain,
osteoarthritis (OA), and other musculoskeletal disorders
represent four of the top nine causes of disability in the
United States and result in more years lived with disabil-
ity than the 12 leading medical causes of disability com-
bined [4]. Chronic pain costs the United States an
estimated $560–635 billion annually, and although
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analgesic medications are one of the most commonly pre-
scribed classes of drugs [5], they have, on average, rela-
tively modest effects on reducing pain and improving
physical functioning. Moreover, increasing awareness of
the risks of opioid analgesics has made this particular
class of analgesics even less desirable as a treatment mo-
dality for the treatment of individuals with chronic pain
[6]. Thus, the Veterans Health Administration (VHA)
Health Services Research and Development Service con-
vened a State-Of-The-Art (SOTA) research conference in
November 2016 focused on nonpharmacological treat-
ments for chronic musculoskeletal pain (CMSP).
One request that emerged from the SOTA was to de-
velop a consensus about core measures for clinical research
investigating CMSP in order to facilitate cross-study com-
parability including the degree of effectiveness of different
treatments. Therefore, the VHA convened a work group for
which the principal charge was “to recommend core out-
come measures for pain intensity and interference to be
used in all VHA prospective clinical research studies of
chronic musculoskeletal pain (both interventional and
observational).” Secondarily, outcome measures for other
important domains were evaluated. Although several other
expert groups have recommended core measures for pain
research, priorities for the present group included not only
strong psychometrics of measures but also pragmatic issues
such as brevity, applicability to any type of CMSP (rather
than a specific condition only such as low back pain or oste-
oarthritis), and utility in studies that may incorporate
patient-reported outcomes in practice-based research and
electronic health records.
Methods
Pain Measures Work Group Process
An 11-member Pain Measures Work Group (PMWG)
composed of VHA and non-VHA individuals with exper-
tise in pain research, measurement development, and psy-
chometrics was appointed and completed its task over 12
months (January through December 2017). The process
involved 1) eight conference calls (90 minutes each); 2) a
one-day in-person meeting; 3) evaluating the results of a
systematic review on pain intensity and interference
measures (see below) [7,8]; 4) reviewing and comparing
the recommendations of several previous consensus
reports [9–11]; 5) conducting two Delphi surveys of
PMWG members to identify core domains and desirable
characteristics of pain measures and to achieve consensus
on the final outcome measures to recommend. This pro-
cess was adapted from guidelines for developing core
outcome sets for research [12].
Systematic Review of Pain Intensity and
Interference Measures
To inform the PMWG, the VHA sponsored a systematic
review of pain intensity and interference measures
through its Evidence-based Synthesis Program (ESP).
Intensity refers to the severity of the pain (the two terms
are often used interchangeably), and interference refers
to the effect of pain on specific areas of functioning. The
PMWG members, as well as key participants with exper-
tise in pain measurement who had attended the SOTA,
identified a list of 17 potential measures for the ESP to re-
view. Published in detail elsewhere [7,8], the ESP report
identified 43 articles that met the inclusion criteria of 1)
evaluating at least one of the 17 pain measures; 2) includ-
ing adults with chronic musculoskeletal pain of at least
three months’ duration or adults with musculoskeletal
pain described as “chronic” by the study authors; and 3)
reporting on at least one of the four psychometric out-
comes—minimally important difference, reliability, va-
lidity, and responsiveness to change. The ESP systematic
review excluded 1) studies that used non-English-lan-
guage versions of the pain measures; 2) studies of acute
musculoskeletal pain or studies of musculoskeletal condi-
tions often associated with chronic pain that did not
specify the presence or duration of their participants’
pain; 3) intervention trials, unless the trial also assessed
the psychometric properties of their measures and noted
this in the abstract; and 4) studies of patients with rheu-
matoid arthritis, orofacial pain other than temporoman-
dibular disorder, or headache.
Recommendations by Other Expert Groups
Three other reports relevant to the PMWG’s charge were
identified and reviewed, including the 1) Initiative on
Methods, Measurement, and Pain Assessment in Clinical
Trials (IMMPACT) [9,13]; 2) National Institute of
Health Task Force on Research Standards for Chronic
Low Back Pain [10]; 3) Core Outcome Set steering group
recommendations for nonspecific LBP research [11,14].
Other literature syntheses were reviewed but in general
did not achieve consensus on specific measures [15–17].
Delphi Surveys
Two surveys of PMWG members using a Delphi process
were conducted. The first survey identified and priori-
tized core outcome domains for CMSP clinical research,
and the second survey achieved consensus on a recom-
mended measure for each domain.
Results
Defining Chronic Pain
Although not an outcome measure, the definition of
chronic pain is also considered important to CMSP re-
search. The National Health Interview Survey (NHIS)
defines chronic pain as pain that has been present on
most days for the past three months [18], whereas the
National Institutes of Health (NIH) Task Force defines it
as pain for at least three months that has been present on
more than half of the days in the past six months [10].
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The PMWG favors the NHIS definition due to its sim-
plicity and its extensive use in epidemiological surveys.
Also, the two definitions are conceptually equivalent in
that both approximate an accumulation of three months’
worth of pain days.
Systematic Review of Pain Intensity and
Interference Measures
Table 1 summarizes psychometric data on the 17 pain in-
tensity and interference measures included in the ESP sys-
tematic review [7,8]. Citations for these measures are
available in the ESP report. The table was adapted from
original tables in the ESP review with two important
modifications. First, data from three recent Department
of Veterans Affairs (VA) trials comprising 759 patients
[19] have been added. Second, the type of response
options (numeric vs verbal) for each scale has been noted.
The pain intensity and interference measures with the
strongest psychometric data include three numeric (nu-
merical rating scale [NRS], Brief Pain Inventory [BPI],
and Pain intensity and pain interference with Enjoyment
of life and General activities [PEG] and two verbal
(Patient-Reported Outcome Information System
[PROMIS] and Short-Form 36 [SF-36]) rating scales.
Some scales measure intensity/severity or interference
only, others have subscales for both domains, and two
(PEG, SF-36) provide a single composite score that
includes both domains. Other scales with substantial psy-
chometric evidence, such as the Roland Morris Disability
Questionnaire (RMDQ) and Oswestry Disability Index
(ODI) for low back pain and the WOMAC for osteoar-
thritis, focus on condition-specific types of musculoskele-
tal pain. As the PMWG charge was to recommend
general measures (i.e., ones that could be used across dif-
ferent types of CMSP conditions), condition-specific
measures were not further considered. One other general
scale with moderate evidence is the visual analog scale
(VAS), but because it is similar in purpose to the single-
item NRS and the latter has much more psychometric ev-
idence [8] as well as several practical advantages (patient
preferences, fewer missing data) [9], the VAS was not fur-
ther considered.
Responsiveness of Pain Intensity and Interference
Measures
Table 2 summarizes the area under the curve (AUC) for
detecting pain improvement using data from seven stud-
ies for eight different scales [19–23]. The original table in
the ESP review [7] has been augmented by data from the
three recent VHA trials [19]. In estimating the AUC, the
data from these three trials involved 594 instead of 759
participants as longitudinal (two time points) rather than
cross-sectional data are required to calculate AUCs for
improvement. AUCs for pain improvement ranged from
0.61 to 0.77. Whereas good AUCs for diagnostic tests
compared with a criterion standard typically exceed
0.80, a reasonable AUC for the ability of a measure to
detect improvement is often somewhat lower (0.65 or
higher) [20,21,24,25]. Moreover, the key purpose of our
report is to assess the comparative rather than absolute
responsiveness of different pain intensity and interference
measures.
Table 3 summarizes data from five trials on another
measure of responsiveness—standardized response mean
(SRM)—which in this case was the standardized changes
in the scale score between baseline and follow-up assess-
ments among patients who rate their pain at follow-up as
“better,” “unchanged (same),” or “worse.” The SRM
data from two trials (SCAMP, SCOPE) have been pub-
lished [20,21], whereas some psychometric data (but not
the SRM findings) from the other three trials have been
reported [19]. The measures with the most evidence to es-
timate SRMs across trials were the BPI interference (five
trials), PEG (five trials), and PROMIS (four trials) scales,
followed by the SF-36 (three trials). The average SRM
across trials for these four scales in patients who reported
pain improvement ranged from 0.56 to 0.84; for those
who reported their pain being the same, 0.31 to 0.38;
and for those who reported their pain as worse, 0.09 to
0.24. Interpretation of SRMs is similar to that of effect
sizes, where 0.2, 0.5, and 0.8 represent small, moderate,
and large changes, respectively [26]. Three findings
should be noted. First, the SRMs for improvement and
worsening were not symmetric; the SRMs for improve-
ment were substantially larger in absolute magnitude
than the SRMs for worsening. Second, although SRMs
for the unchanged group typically did not center on 0,
they were not as large as the SRMs for improvement.
Third, the SRMs for the improved, unchanged, and
worse groups differed significantly from one another,
meaning the scales differentiated among the three groups.
These findings are consistent with previous reports
[20,21,24].
Recommended Measures by Other Expert Groups
Table 4 compares the core domains and specific measures
recommended by various expert groups [7,9,10,14]. The
NRS and BPI interference scales are the most commonly
recommended pain intensity and interference measures,
respectively.
PMWG Prioritized Secondary Domains and
Recommended Measures
Table 5 shows the PMWG’s prioritized domains and rec-
ommended measure for each domain. Panelists rated
each domain as 1 (important), 2 (very important), or 3
(essential). After pain intensity and inference, the next
most highly ranked domains were physical functioning
and depression (2.4 each), followed by anxiety (1.7),
sleep (1.4), and patient-rated change (1.3). The NRS (one
item) and BPI (seven items) are the measures endorsed
for assessment of pain intensity and interference,
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respectively. For secondary domains, the recommended
measures are the Patient Health Questionnaire two-item
depression scale (PHQ-2) for depression, Generalized
Anxiety Disorder two-item anxiety scale (GAD-2) for
anxiety, and PROMIS four-item scales for physical func-
tion and sleep. Fatigue and pain catastrophizing were dis-
cussed as potential domains but were not recommended
as core measures due to greater uncertainty about treat-
ability, lack of endorsement by other expert groups, and
the desire to limit the number of domains to those consid-
ered most important. The final set of measures recom-
mended by the PWMQ are included in the
Supplementary Data.
PWMG members were asked to rank the importance
of secondary (nonpsychometric) characteristics of pain
measures on a 1 (low importance) to 5 (high importance)
scale. The secondary scale characteristics most highly
rated included the scale being public domain (i.e., no fee
to use), brief, and feasible for clinical use (all with a me-
dian rating of 5), followed by feasibility of incorporating
it into electronic health records (4.0), emerging/increas-
ing use (3.0), number of studies that have used the mea-
sure (3.0), and number of translations into languages
other than English (2.0). Although not ranked, other de-
sirable characteristics suggested by a few PMWG mem-
bers included simplicity of scoring, clinically
interpretable cut-points, and data on cross-walking
scores with other measures.
A single measure rather than several options was rec-
ommended for each domain to encourage common met-
rics that would facilitate direct comparison of results
across different studies. The closest competitors to sec-
ondary domain scales that were ultimately chosen in-
cluded the SF-36 (10 items) for physical function; the
PHQ-9 (nine items) and PROMIS (four items) scales for
depression; the brief Pittsburgh Insomnia Scale (two
items) for sleep; and the GAD-7 (seven items) and
PROMIS (four items) for anxiety.
Discussion
The PMWG’s principal charge was to recommend core
pain intensity and interference measures to be included in
prospective studies focused on chronic musculoskeletal
pain. Findings from the ESP systematic review aug-
mented by three recent studies did not identify a clear





















Numerical rating scale (NRS) Numeric 11 1,653 1 3 5 4 2 S Yes
Brief Pain Inventory (BPI) Numeric 9 2,590 11 4 9 6 SþI No
PEG Numeric 6 1,765 3 4 6 4 SI comp Yes
Patient-Reported Outcome
Information System (PROMIS)
Verbal 7 1,458 4-8 3 6 4 1 I Yes
SF-36 Bodily Pain Scale Verbal 11 2,308 2 2 6 8 SI comp No
Graded Chronic Pain Scale (GCPS) Numeric 3 1,058 12 1 2 2 SþI Yes
McGill Pain Questionnaire (MPQ) Verbal 3 366 78† 1 2 1 S Yes
Multidimensional Pain
Inventory (MPI)
Numeric 4 708 9 1 4 1 SþI Yes
Visual analog scale (VAS) Numeric 8 541 1 2 2 3 3 S Yes
Patient global impression
of change (PGIC)
Verbal 1 476 1 1 n/a Yes
Disorder-specific
Oswestry Disability Index (ODI) Verbal 10 1,149 10 3 5 6 3 SþI No
Roland Morris Disability
Questionnaire (RMDQ)
Verbal 10 4,157 24 4 5 6 1 I Yes
Western Ontario McMasters
Osteoarthritis Index (WOMAC)
Verbal 5 535 24 3 2 1 SþI No
Minimal evidence
Wong Faces Scale Numeric 1 32 1 1 S No
Hip disability and Osteoarthritis
Outcome Score (HOOS)
Verbal 1 62 40 1 1 SþI Yes
Knee injury and Osteoarthritis
Outcome Score (KOOS)
Verbal 0 42 SþI Yes
Defense & Veterans Pain
Rating Scale (DVPRS)
Numeric 0 5 SþI Yes
I ¼ interference score only; MID ¼ minimally important difference; S ¼ severity (intensity) score only; Sþ I ¼ separate severity and interference scores; SI
comp ¼ composite severity-interference score.
*Table was adapted from Goldsmith et al. [7,8], including the addition of data from Chen et al. [19] from three other trials.
†Pain Rating Index based on 78 pain descriptors; Present Pain Intensity based on six additional items.
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“psychometric winner” but instead several psychometri-
cally valid scales from which to choose. Although psy-
chometric soundness was considered a necessary
criterion, it could not be the sole deciding factor for sev-
eral reasons: 1) the ESP review found only a small num-
ber of studies for any given measure; 2) there were
substantial methodological and population differences
across these studies; 3) studies comparing the same meas-
ures across different populations can show substantial
psychometric differences; 4) studies comparing different
measures within the same population tend to show rela-
tively comparable responsiveness.
It is important to acknowledge that the recommenda-
tions of the PMWG are directly related to its specific
charge, namely, to focus on pain intensity and interfer-
ence. The recommendations of the PMWG should not be
taken as precluding the inclusion of other important
domains both in clinical practice and research. The inclu-
sion of other domains and additional measures should be
directly related to the questions of particular interest
addressed by a clinician or a clinical researcher. In addi-
tion, we are not suggesting which measures should be
used as the primary outcome for studies. For example, a
study focused exclusively on low back pain could include
the PMWG measures but still select a validated LBP scale
as the primary outcome (plus items that capture LBP-
unique features such as the radicular pain of sciatica).
For several reasons, the PMWG recommends the NRS
(one item) and BPI interference scale (seven items) as
minimum core measures to assess pain intensity and in-
terference, respectively. First, rating scales with numeric
rather than verbal response options have a somewhat
longer track record of use in clinical trials and other re-
search studies. Second, the cut-points for differing levels
of pain on 0–10 NRS have been extensively studied. For
example, one common cut-point range (1–3 representing
mild pain, 4–6 moderate pain, and 7–10 severe pain) has
been used in major VHA quality improvement initiatives
[27]. A recent literature synthesis suggests 1–4, 5–6, and
7–10 as evidence-based ranges [28]. Third, the
Table 4. Core domains/measures recommended by other groups for pain research
Recommended Scale (No. of Items)
Domain (Pain Site)














Pain intensity NRS (1) BPI (4) NRS (1) NRS (1) NRS (1), VAS (1), MPQ (78) NRS (1)
Pain interference PROMIS (4) BPI (7) BPI (7) or MPI (9) BPI (7) or MPI (9) BPI (7), PEG (3), SF-36 (2),
MPI (9), GCPS (7)
BPI (7)
Physical function PROMIS (4) RMDQ (24) or
ODI (10)
SF-36 (10) RMDQ (24) or
ODI (10)
RMDS (24), ODI (10),
WOMAC (24)
PROMIS (4)
Depression PROMIS (4) PHQ-9 or BDI BDI and xc POMS HADS (7) PHQ-2 (2)
Sleep PROMIS (4) PROMIS (4)
Patient-rated change PGIC (1) PGIC (1)
Anxiety HADS (7) GAD-2 (2)
Work disability 2 items 1–2 items
Other * †
BDI¼Beck Depression Inventory; GAD-2¼Generalized Anxiety Disorder two-item anxiety scale; HADS¼Hospital Anxiety and Depression Scale;
MPI¼Multidimensional Pain Inventory; MPQ ¼McGill Pain Questionnaire; ODI¼Oswestry Disability Index; NRS¼numerical rating scale; PGIC¼patient-rated
global impression of change; PHQ-2¼ Patient Health Questionnaire two-item depression scale; POMS¼Profile of Mood States; PROMIS¼Patient-Reported
Outcomes Measurement Information System; RMDQ¼Roland Morris Disability Questionnaire; VAS¼visual analog scale; WOMAC¼Western Ontario
McMasters Osteoarthritis Index.
*Other domains (No. of items) include substance use (tobacco, alcohol, drugs; 3), other pain sites (5), prior surgery (3), pain treatments (4),
catastrophizing (1).
†Other domains (No. of items) include health-related quality of life (5–12).




Rating* Recommended Measure Items
Pain intensity 3.0 Numerical rating scale (NRS) 1
Pain interference 3.0 Brief Pain Inventory (BPI)† 7
Physical function 2.4 PROMIS Profile–29 4
Depression 2.4 Patient Health
Questionnaire–2 (PHQ-2)
2
Anxiety 1.7 Generalized Anxiety
Disorder–2 (GAD-2)
2
Sleep 1.4 PROMIS Profile–29 4
Global change 1.3 Patient global impression
of change (PGIC)
1
*Mean importance rating of domain by 10 expert panelists, assigning three
points for essential, two points for very important, and one point for
important.
†For permission to use the Brief Pain Inventory, go to its developers’ website:
https://www.mdanderson.org/research/departments-labs-institutes/departments-
divisions/symptom-research/symptom-assessment-tools/brief-pain-inventory.html.







edicine/article/20/8/1500/5274160 by guest on 21 O
ctober 2020
responsiveness of the BPI and NRS equals or exceeds that
of the most-studied verbal response scales (PROMIS and
SF-36), as shown in Tables 2 and 3. Fourth, the BPI and
NRS are the most commonly recommended measures by
other expert groups (Table 4). Although the evidence is
inconclusive regarding how well verbal ratings of pain
correspond to numerical ratings [21,29], methods pro-
viding a cross-walk between the two types of ratings
have been developed [19,30,31].
Use of the BPI does require permission from its devel-
opers, and in some circumstances a modest fee. If this is a
barrier to use for some researchers or clinicians, two al-
ternative options using public domain measures are 1)
the NRS for pain severity and the PROMIS (four items)
for pain interference or 2) the three-item PEG, which
includes the NRS plus two items from the BPI and pro-
vides a composite severity-interference score. Nonetheless,
the PMWG recommends that VHA researchers include
the NRS and BPI as a minimal data set to facilitate cross-
study comparisons using common metrics.
There is some debate as to whether pain intensity and
pain interference need to be assessed as separate domains
vs a single composite score. Although the separate do-
main approach has been traditionally favored, some re-
cent evidence shows that composite scales such as the
PEG, BPI total score, and SF-36 bodily pain scale per-
form similarly to separate scores [19–21,24]. Composite
scales have the additional advantage of providing a single
measure as a primary outcome in research studies as well
as a single score with which clinicians can monitor out-
comes and adjust treatment. The brevity of a composite
measure like the PEG may also be suited to studies where
pain is a secondary outcome and a smaller number of
items is desirable. Nonetheless, the core outcomes recom-
mended by the PMWG include separate measures of pain
intensity and interference.
Three measures for which the ESP review provided
substantial evidence include two for LBP (RMDQ and
ODI) and one for OA (WOMAC). Because the PMWG
sought measures that could be used across all studies re-
gardless of CMSP condition, these three condition-
specific measures were not deemed eligible for the core
measure set. However, they are certainly strong measures
for LBP and OA research, although we also recommend
inclusion of the core measures in Table 5. Of note, the
RMDQ has been adapted for research that includes
patients with CMSP other than LBP [32–35]. It is also
available in a shorter 11-item version [36].
IMMPACT is the other expert group to have provided
recommendations for pain measures that were not
condition-specific. Our PMWG report differs from
IMMPACT in several ways. First, there have been new
pain measures and some advances in the psychometric re-
search since the IMMPACT report was published
15 years ago. Second, IMMPACT provided more than
one option for several domains, whereas a principal in-
tent of PMWG deliberations was to recommend only one
measure for each domain so that a common set of meas-
ures might be used across different pain studies. Third,
brevity of measures was an important aim of the PMWG
in order to maximize the use of core measures across
many types of research settings, including practice-based
studies and those using the electronic health record.
A key issue was whether to preferentially recommend
a PROMIS measure when it was available for a specific
domain. Strengths of PROMIS measures include heavy
investment by the NIH in rigorous psychometric develop-
ment, their grounding in item-response theory, the ability
to obtain highly reliable scores by completion of fewer
than 10 items when administered by computer adaptive
testing (CAT), and conversion of raw to T-scores, for
which 50 represents the population norm regardless of
domain. However, CAT administration is not yet feasible
across all research and clinical settings. Also, some scale
users find responses to individual items useful (comple-
menting the overall scale score), preferring fixed-item
scales where the same items are administered at each as-
sessment. PROMIS does provide the option of fixed-item
scales (which are included for some domains by the NIH
Task Force and a few domains by our VHA PMWG).
However, the advantages of PROMIS measures are
somewhat attenuated when PROMIS fixed-length scales
are compared with non-PROMIS legacy scales, such as
the BPI for pain interference, the PHQ-9/PHQ-2 for de-
pression, and the GAD-7/GAD-2 for anxiety. In these
domains, the PROMIS scales do not yet have as strong a
track record in clinical trials and other research.
However, with increasing use of PROMIS measures, it is
good that cross-walks between PROMIS and non-
PROMIS legacy scales are available [19,31,37].
At a minimum, the PMWG recommends that common
measures of pain intensity and interference be used across
all prospective clinical studies of CMSP. The other
domains in Table 5 would be desirable to include when-
ever possible. For example, a general measure of physical
functioning does not require individuals with chronic pain
and comorbid medical and mental conditions to decide
how much of their functional impairment is attributable
to chronic pain vs other concurrent disorders (an often dif-
ficult task). The focus on brief measures for both primary
and secondary domains is driven by the desire to minimize
respondent burden and to encourage use in pragmatic tri-
als, which may depend upon measures routinely gathered
in clinical care and incorporated into electronic medical
records. Individuals can typically complete around four
items per minute; thus, the BPI plus NRS should only take
a few minutes to complete and, even with the addition of
the secondary measures in Table 5, no longer than five
minutes. As pain is ubiquitous across most medical and
mental disorders, the availability of brief public domain
measures may encourage assessment of pain as a second-
ary outcome in many other areas of clinical research.
Although the anticipated initial audience for this re-
port is VHA researchers, four of the PMWG members
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were clinical researchers from outside the VHA. Also,
much of the evidence supporting the recommended meas-
ures was generated in nonveteran samples. Thus, the rec-
ommendations are likely relevant to clinical research
outside the VHA. Finally, although the targeted condi-
tion was chronic musculoskeletal pain, the recommended
domains and measures may also be applicable across
non-CMSP pain disorders. This is especially salient given
the fact that many patients with chronic pain report pain
across multiple musculoskeletal and nonmusculoskeletal
locations [38,39]. Thus, brief pain measures that are not
restricted to a specific bodily site may serve as valuable
common metrics across pain studies, even when longer or
more disease-specific measures are used as primary
outcomes.
Supplementary Data
Supplementary data are available at Pain Medicine
online.
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